QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$116.98
+0.95 (+0.82%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$115.03
$117.11
50-Day Range
$88.31
$116.98
52-Week Range
$70.73
$117.11
Volume
1.34 million shs
Average Volume
1.76 million shs
Market Capitalization
$21.70 billion
P/E Ratio
278.52
Dividend Yield
N/A
Price Target
$120.12

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
2.7% Upside
$120.12 Price Target
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.65mentions of BioMarin Pharmaceutical in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$4.71 M Sold Last Quarter
Proj. Earnings Growth
165.91%
From $0.88 to $2.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

357th out of 1,048 stocks

Pharmaceutical Preparations Industry

171st out of 513 stocks


BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

BioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $132.00
Stocks News Announcement
Don't miss this update. Read the press release about Small Pharma.
Stocks News Announcement
Don't miss this update. Read the press release about Small Pharma.
6 Analysts Have This to Say About Biomarin Pharmaceutical
Deals, data kick off biotech's big JPM Week
BioMarin Pharmaceutical Inc. (BMRN)
Biotech Stock Finds Favor Among Mutual Fund Managers
BMRN BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical - Solutions For Rare Illnesses
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
10/26/2021
Today
1/26/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,045
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$120.12
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$83.00
Forecasted Upside/Downside
+2.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

Net Income
$-64,080,000.00
Pretax Margin
5.01%

Debt

Sales & Book Value

Annual Sales
$1.85 billion
Cash Flow
$0.89 per share
Book Value
$23.26 per share

Miscellaneous

Free Float
182,228,000
Market Cap
$21.70 billion
Optionable
Optionable
Beta
0.36

Social Links


Key Executives

  • Mr. Jean-Jacques  Bienaime M.B.A.Mr. Jean-Jacques Bienaime M.B.A. (Age 70)
    MBA, Chairman & CEO
    Comp: $3.67M
  • Mr. Brian R. MuellerMr. Brian R. Mueller (Age 49)
    Exec. VP of Fin. & CFO
    Comp: $1.13M
  • Dr. C. Greg Guyer Ph.D. (Age 61)
    CTO and Exec. VP of Global Manufacturing & Technical Operations
    Comp: $1.75M
  • Mr. Jeffrey Robert AjerMr. Jeffrey Robert Ajer (Age 61)
    Exec. VP & Chief Commercial Officer
    Comp: $1.2M
  • Dr. Henry J. Fuchs M.D. (Age 65)
    Ph.D., Pres of Worldwide R&D
    Comp: $1.52M
  • Ms. Erin Burkhart
    Group VP & Chief Accounting Officer
  • Traci McCarty
    VP of Investor Relations
  • Mr. George Eric DavisMr. George Eric Davis (Age 52)
    Exec. VP & Chief Legal Officer
  • Mr. Philip Lo Scalzo
    Sr. VP & Chief Compliance Officer
  • Ms. Humaira Serajuddin
    Sr. VP & Chief Marketing Officer













BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2023?

14 Wall Street analysts have issued 1 year price targets for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $83.00 to $200.00. On average, they expect the company's stock price to reach $120.12 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN shares have increased by 13.1% and is now trading at $117.01.
View the best growth stocks for 2023 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 6,700,000 shares, a drop of 35.3% from the December 31st total of 10,360,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is presently 4.3 days. Currently, 3.7% of the company's stock are short sold.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Tuesday, October, 26th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.05. The biotechnology company earned $408.74 million during the quarter, compared to analyst estimates of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.50% and a net margin of 4.18%. The business's revenue for the quarter was down 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 earnings per share.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.38%), Scout Investments Inc. (0.30%), DNB Asset Management AS (0.25%), Allspring Global Investments Holdings LLC (0.23%), CMH Wealth Management LLC (0.02%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $117.01.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $21.70 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,045 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 1/26/2023 by MarketBeat.com Staff